University of Liverpool

Norwich University

Webster University

Webster University (AT)

Serial entrepreneur, globally connected, prior VC/PE, public/private/startup, board of drectors

Tampa, Florida, United States

Mosaigen was founded in 2004 as a global technology development corporation specializing in the life sciences, ICT and Cleantech industries.

Our portfolio company projects are globally oriented. The company is headquartered in the Greater Tampa region and Washington D.C.with affiliate groups in Europe and Asia.

Our proprietary venture creation/acceleration model "reverse startup" approach combines assets, people and money into new or existing entities to develop well run, capital efficient, lower risk companies. We work with leading universities and entrepreneurs to turn their dreams into commercially viable products and technologies.

Our focus is:

-  Nanotechnology & Material Sciences

-  Life Sciences (Pharma, Device, Diagnostics, Research, OTC/CPG)

-  ICT (High performance computing, Web 2.0, Machine Learning, Pattern Recognition/Dynamic Scaffolding, Virtualization platforms, Simulation, Physics Engines and New Media)

-  Clean/Green Tech (Solar, Wind, Smart Software, Materials, renewable Energy, non-food stock biofuels & ISBEs)

Mosaigen Corporation

Executive Chairman

A national investment fund oriented towards growth capital opportunities in science and technology with a focus in genomics, big data and personalized medicine. The funding is derived from the UK government with majority of funds from the Scottish government. This fund is a feeder fund and syndicates with both private and public sources of capital in Europe and North America.

Genomic Medicine Catalyst Investment Fund

Investment Committee

Bioscience trade/lobby organization for all sectors representing Pennsylvania bioscience companies. Member of the Medical Device & Diagnostics Committee. <a href="http://www.lifesciencespa.org/">http://www.lifesciencespa.org/</a>

Life Science PA /BIO

Board Of Directors

Scotland has always made its presence felt in the world of international business, earning an impressive reputation for Innovation, drive and entrepreneurial expertise. GlobalScot Advisors seek to develop and expand Scotland's standing in the global business community by utilising the talents of leading Scots, and of people with an affinity for Scotland, to establish a worldwide network of individuals who are outstanding in their field.  Since the formation of GlobalScot in 2001, we have already achieved significant results with many Scottish companies, proving that GlobalScots can - and do - make a real difference to the Scottish economy.

Advisory Board, Scottish Government- GlobalScots

Consultant

Created by Maryland Legislature in 1998 for technology transfer from universities and federal                labs that provides investment funding, mentoring and professional networking. <a href="http://tedco.md/">http://tedco.md/</a>

Maryland Technology Development Corporation (TEDCO)

Entrepreneur Mentoring Board

<a href="http://www.celios.com">www.celios.com</a>

Medical & Non-medical devices

Celios Corporation

Chairman, CEO and Founder

A private Investment Group in science & technology sectors - Blended investment approach with early, mid, late, crossover and on-market stages in science & technology sectors. Our investment thesis is heavily commercially-driven with our harvesting strategy involving two or more exits from each portfolio company project. We utilize traditional and alternative investment and business strategies to gain accretive advantages prior to our exits. Some commercial/investment vehicles we deploy are business roll-ups, asset purchase, repurposing, reverse start-up and buy-in-build approaches. Our investment goals focus on one of the following: 1) turn-around of stagnant or ‘zone of insolvency’ companies, dormant intellectual property, commercial assets, restarts of secondary assets companies and lastly, our ‘bolt-on and build’ models that provide accretion in at least two parallel, but non-competing market segments. This parallelism allows for the monetization of core assets, science and technologies to be harvested to more than one large suitor. We work with varied sources of capital as well as universities and corporate organizations that are striving for asset growth and monetization. Our focus is on a globalized basis.

Dog River Ventures

Managing Partner

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Our novel molecular and cellular markers and bioinformatics services allow physicians to characterize malignant tumors and are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer. Helomics was acquire by a private investment group in December of 2016.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains CLIA-certified laboratories.  For more information on the NEW Helomics please visit: <a href="http://www.helomics.com">www.helomics.com</a>

Helomics Corporation

President & CEO

About HealthCare Royalty Partners
HealthCare Royalty Partners ("HC Royalty") is a $3.0+ billion global healthcare investment firm. HC Royalty invests primarily in commercial stage healthcare assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, the senior investment team has completed more than 60 royalty investments valued in excess of $2.5 billion.

Our philosophy is simple. Identify compelling investment opportunities that will generate significant long-term value for our partners and our investors. We currently manage over $3.0 billion in capital across four investment funds.

For more information, visit <a href="http://www.healthcareroyalty.com">www.healthcareroyalty.com</a>.

HealthCare Royalty Partners

Advisor & Operating Partner

nanomedicine, high-performance teams and organizations in science & technology

Senior Research Fellow

Ranked #1 in Asia and in top 20 in combined world rankings for universities science & technology

Hong Kong University of Science & Technology (HKUST)

Visiting Scholar, Bionanotechnology & Chemistry

About SuperNova Diagnostics, Inc.

SuperNova is a early commercial stage diagnostics company with a proprietary diagnostics platform that greatly enables point-of-care in human health and point-of-use for non-human health applications.

A powerful proprietary nanochemistry, AmpCrystal™, can delivery novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements.

Can also be utilized in a wide range of diagnostic formats (disposable cartridges, lateral flow, microtitre, arrays, OEM, etc.)

SuperNova Diagnostics, Inc.

President & CEO, Co-Founder

CureKids™ is an innovative children’s charity investing in children’s lives by accelerating science and technology and catalytically bringing together the social entrepreneur with the socially-minded donor to bring about change in how philanthropic giving can make a difference in commercializing products & services in life sciences, IT and education to eradicate disorders and diseases in children.

CureKids was established more than 30 years ago to address the lack of research into life-threatening childhood illness in New Zealand and has since become an international organization.

Since then, the organization has invested more than $30 million in medical R&D and commercialization. This social investments has helped save hundreds of young lives and has improved the quality of life for thousands of children around the world. Our model is based upon the most leading edge venture philanthropy strategies for social investment.

CureKids - Child Health Research Institute

Chairman

Established in 1999, Endeavour Capital a leading Asia/Pacific investment company with a focus on developing globally competitive companies based on science and technology innovations. Endeavour has made investments across biotechnology, software, cleantech, healthcare and medical device sectors.

The Endeavour Team is comprised of experienced entrepreneurs and investment professionals, each having key involvement in building and exiting at least one significant company in Asia/Pacific or USA.

Our model is to provide portfolio companies with significant operational, commercial and technical resources, complemented with capital. In order to assist with international growth plans, the Endeavour Capital managers form a partnership with the founders and key staff to maximize a company's worldwide opportunities.

We can make investments in Asia/Pacific, EU zone, Gulf Region and look to U.S.A. for investment deals, limited partners and for us to locate promising companies.

Endeavour Capital

General Partner

Adjunct Professor (practitioner faculty)of Business & Entrepreneurship in the Carey Graduate School of Business in conjunction with joint program with Johns Hopkins School of Medicine teaching courses in corporate & organizational finance, venture creation topics and entrepreneurship/leadership.

Johns Hopkins University

Adjunct Professor Carey Graduate School of Business

EntreMed is a public (NASDAQ), clinical-stage (Phase II) biopharmaceutical company developing therapeutics for disease indications of cancer, ophthalmology, cardiovascular, dermatology, bone, inflammation and woman's health.

-  (All public information available through SEC filings) Appointed principal chief executive (acting CEO) tasked with saving the company when only three months of available cash remained.   Settled major litigation with Celgene & Abbott, NASDAQ delisting notification and over $15M in debt over-hang.
-  Proactively orchestrated financial and corporate transactions totaling $150.2M over 3 year period.
-  Negotiated out-license and assignment of rights for Angiostatin & Endostatin proteins (Phase II); gene therapy eye deal with Oxford BioMedica in UK;Phase I deal Celgene Corporation in December, 2002( deal was completed with only 4.5 days of cash on hand)Thalidomide analogs;Allergan for ophthalmologic pharmaceuticals  in January 2002.

EntreMed, Inc.

President & CEO/COO

The Advisory Board of Beachheads programmes helps New Zealand and NZ-Associated companies succeed domestically and internationally by providing access to private sector advisors, direct investments and their top quality international networks.

New Zealand Government-NZTE

Advisory Board

Worldwide commercial director for Celera's Discovery e-Commerce web-based portal and supporting genomic and proteomic database products and services. Position combined sales & marketing with original business development activities with full P&L in establishing new business opportunities and custom products in drug discovery, supporting clinical drug programs and disease evidence-based programs.  Worked with various groups to help setup and establish activities in Japan for Celera Japan and interactions with Japanese Pharma & Biotech companies. Also signed first country-wide deal with Australia and first University Partnership with Vanderbilt University.

Celera Genomics

Senior Director, Commercial Development

Global Business Director for Cell & Molecular Biology business, services and e-commerce with full P&L responsibilities. Established or expanded sales revenues and offices in North America, Europe, Middle East, India, South East Asia, Japan and Oceania. Our business group created, developed and launched over 40 new products during tenure of position to include the Platinum Molecular Biology line.

Life Technologies

Director of Worldwide Business Cell & Molecular Biology

GM for small-scale biosensor technologies for analysis of proteins, DNA and RNA. Applications were high throughput drug screening, point of care diagnostic testing, point of use diagnostics for food, beverage and biosecurity and central laboratory testing utilizing electrochemiluminence self-contained sensors. Worked with strategic partners, Eisai Pharma (Japan), Boerhringer Mannheim (Germany) and Perkin-Elmer/ABI  (United States) for NASBA DNA.

IGEN International (Now Roche)

General Manager & Program Director

Various Sales & Marketing, business development positions in the Diagnostics Division (ADD) and special program division in marketing with the Pharmaceutical and Hospital products divisions with the physician office marketplace
Locations were New York City Area, New England (Boston Region) and headquarters in North Chicago (Abbott Park), Illinois.

Neil Campbell

Neil Campbell